These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 31278785

  • 21. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.
    Felipe C, Ferreira AN, de Paula M, Viana L, Cristelli M, Medina Pestana J, Tedesco-Silva H.
    Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566
    [Abstract] [Full Text] [Related]

  • 22. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
    Cristelli MP, Esmeraldo RM, Pinto CM, Sandes-Freitas TV, Felipe C, Lobo CF, Viana L, Mansur J, Stopa S, Santos DWC, Grenzi PC, Aguiar WF, Tedesco-Silva H, Pestana JOM.
    Transpl Infect Dis; 2018 Aug; 20(4):e12907. PubMed ID: 29679515
    [Abstract] [Full Text] [Related]

  • 23. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
    Martin ST, Roberts KL, Malek SK, Tullius SG, Vadivel N, De Serres S, Grafals M, Elsanjak A, Filkins BA, Chandraker A, Gabardi S.
    Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
    [Abstract] [Full Text] [Related]

  • 24. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Nashan B, Thaiss F.
    Trials; 2016 Feb 17; 17():92. PubMed ID: 26888217
    [Abstract] [Full Text] [Related]

  • 25. 5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment.
    Hiramitsu T, Okada M, Futamura K, Yamamoto T, Tsujita M, Goto N, Narumi S, Watarai Y, Takeda A, Iwasaki K, Uchida K, Kobayashi T.
    Int Immunopharmacol; 2016 Oct 17; 39():192-198. PubMed ID: 27491025
    [Abstract] [Full Text] [Related]

  • 26. Outcomes of Early Steroid Withdrawal in Recipients of Deceased-Donor Expanded Criteria Kidney Transplants in the Era of Induction Therapy.
    Hussain SM, Marcus RJ, Ko TY, Nashar K, Thai NL, Sureshkumar KK.
    Exp Clin Transplant; 2016 Jun 17; 14(3):287-93. PubMed ID: 27221720
    [Abstract] [Full Text] [Related]

  • 27. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
    Viganò M, Dengler T, Mattei MF, Poncelet A, Vanhaecke J, Vermes E, Kleinloog R, Li Y, Gezahegen Y, Delgado JF, RAD A2411 Study Investigators.
    Transpl Infect Dis; 2010 Feb 17; 12(1):23-30. PubMed ID: 19744284
    [Abstract] [Full Text] [Related]

  • 28. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O, Wiesener M, Opgenoorth M, Pascher A, Woitas RP, Witzke O, Jaenigen B, Rentsch M, Wolters H, Rath T, Cingöz T, Benck U, Banas B, Hugo C.
    Lancet; 2016 Dec 17; 388(10063):3006-3016. PubMed ID: 27871759
    [Abstract] [Full Text] [Related]

  • 29. Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal.
    Tönshoff B, Tedesco-Silva H, Ettenger R, Christian M, Bjerre A, Dello Strologo L, Marks SD, Pape L, Veldandi U, Lopez P, Cousin M, Pandey P, Meier M.
    Am J Transplant; 2021 Jan 17; 21(1):123-137. PubMed ID: 32406111
    [Abstract] [Full Text] [Related]

  • 30. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
    Traitanon O, Mathew JM, Shetty A, Bontha SV, Maluf DG, El Kassis Y, Park SH, Han J, Ansari MJ, Leventhal JR, Mas V, Gallon L.
    PLoS One; 2019 Jan 17; 14(5):e0216300. PubMed ID: 31136582
    [Abstract] [Full Text] [Related]

  • 31. Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients.
    Taber DJ, Chokkalingam A, Su Z, Self S, Miller D, Srinivas T.
    Clin Transplant; 2019 Oct 17; 33(10):e13679. PubMed ID: 31365151
    [Abstract] [Full Text] [Related]

  • 32. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft.
    Grinyó JM, Gil-Vernet S, Seron D, Hueso M, Fulladosa X, Cruzado JM, Moreso F, Fernandez A, Torras J, Riera L, Castelao AM, Alsina J.
    Nephrol Dial Transplant; 1998 Oct 17; 13(10):2601-4. PubMed ID: 9794567
    [Abstract] [Full Text] [Related]

  • 33. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin.
    Jewani PK, Pouch SM, Kissling KT.
    Clin Transplant; 2018 Nov 17; 32(11):e13420. PubMed ID: 30290013
    [Abstract] [Full Text] [Related]

  • 34. Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation.
    Höcker B, Zencke S, Pape L, Krupka K, Köster L, Fichtner A, Dello Strologo L, Guzzo I, Topaloglu R, Kranz B, König J, Bald M, Webb NJ, Noyan A, Dursun H, Marks S, Ozcakar ZB, Thiel F, Billing H, Pohl M, Fehrenbach H, Schnitzler P, Bruckner T, Ahlenstiel-Grunow T, Tönshoff B.
    Am J Transplant; 2016 Mar 17; 16(3):921-9. PubMed ID: 26613840
    [Abstract] [Full Text] [Related]

  • 35. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
    Nashan B, Schemmer P, Braun F, Dworak M, Wimmer P, Schlitt H.
    Trials; 2015 Mar 26; 16():118. PubMed ID: 25873064
    [Abstract] [Full Text] [Related]

  • 36. Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
    Nogueras López F, Abellan Alfocea P, Ortega Suazo EJ, López Garrido MA, Becerra Massare A, Gila Medina AM, Redondo Cerezo E, Espinosa Aguilar MD.
    Transplant Proc; 2020 Mar 26; 52(2):556-558. PubMed ID: 32035673
    [Abstract] [Full Text] [Related]

  • 37. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.
    Shihab F, Qazi Y, Mulgaonkar S, McCague K, Patel D, Peddi VR, Shaffer D.
    Am J Transplant; 2017 Sep 26; 17(9):2363-2371. PubMed ID: 28141897
    [Abstract] [Full Text] [Related]

  • 38. ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus.
    Rummo OO, Carmellini M, Rostaing L, Oberbauer R, Christiaans MH, Mousson C, Langer RM, Citterio F, Charpentier B, Brown M, Kazeem G, Lehner F, ADHERE study investigators.
    Transpl Int; 2017 Jan 26; 30(1):83-95. PubMed ID: 27754567
    [Abstract] [Full Text] [Related]

  • 39. Outcomes of Everolimus Plus Standard-Dose Tacrolimus Immunosuppression in De Novo Kidney Transplant: A Retrospective, Single-Center Study of 225 Transplants.
    Okabe Y, Noguchi H, Sato Y, Mei T, Kaku K, Ueki K, Tsuchimoto A, Nakamura M.
    Exp Clin Transplant; 2022 Mar 26; 20(4):362-369. PubMed ID: 35475420
    [Abstract] [Full Text] [Related]

  • 40. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
    Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kisilisik AT, Trofe J, Alloway RR, Gaber LW, Gaber AO.
    Transpl Infect Dis; 2001 Mar 26; 3(1):8-15. PubMed ID: 11429034
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.